Investor Relations
Building the future of cancer interception.
Kiluma Biosciences is developing next-generation oncology diagnostics designed to identify disease-associated biological signals earlier — creating opportunities for earlier intervention and potentially improved outcomes.
Large Market Opportunity
Multi-hundred-billion-dollar global oncology and diagnostics opportunity expanding through 2030 and beyond.
Proprietary Platform Technology
Intercept IQ™ — a scalable multiomic architecture integrating cfDNA, epigenetics, proteomics, and AI.
Strong Intellectual Property
Defensible IP position across assay design, biomarkers, and AI-driven interpretation.
Experienced Leadership
Operators and scientists with deep precision-oncology, diagnostics, and capital-markets pedigree.
The Cost of Cancer
One of the largest healthcare challenges in history.
Cancer's human and economic impact is staggering — and growing. Earlier detection represents one of the highest-leverage opportunities in modern healthcare.
0M+
New cancer diagnoses globally each year
$0B+
Global oncology spending annually
0%+ CAGR
Projected oncology market growth
0×
Cancer cases expected by 2050
Investor KPIs
The numbers that define the opportunity.
Hover any metric to see context. Figures are illustrative — drawn from publicly available oncology and diagnostics sources.
0%
Stage I 5-year survival
vs <15% at Stage IV
0%
Pancreatic cancers caught late
Today's standard of care
$0K+
Avg. lifetime cost — late stage
Per patient burden
$0B+
Liquid biopsy TAM by 2030
Fastest-growing diagnostic segment
0×
Survival uplift
Stage I vs Stage IV
0K
U.S. pancreatic cases / yr
~52K deaths annually
Why Early Detection Matters
The difference between Stage I and Stage IV can be everything.
Earlier detection drives better outcomes and significantly lower lifetime cost of care — creating enormous clinical and economic value across the healthcare system.
Market Opportunity
A multi-billion-dollar diagnostic opportunity.
Cancer Diagnostics
$180B+
by 2030
Liquid Biopsy
$25B+
fastest-growing segment
Precision Medicine
$175B+
global opportunity
Multi-Cancer Early Detection
$50B+
emerging category
Companion Diagnostics
$15B+
tied to therapeutic launches
Market figures reflect publicly available analyst projections through 2030+. Growth driven by aging populations, expanding precision-medicine adoption, and increased focus on early detection.
Why Diagnostics Create Value
Diagnostics sit at the center of modern oncology.
Diagnostics create value across the entire patient journey — from initial screening through long-term recurrence monitoring. Few categories in healthcare touch as many decision points.
Therapeutic Enablement
Breakthrough therapies need better diagnostics.
Billions of dollars are being invested in oncology therapeutics. The future of precision oncology depends on the diagnostic infrastructure that surrounds it — Kiluma is building that infrastructure.
Platform Value Creation
More than a test. A data and intelligence platform.
Testing
Clinical-grade assays
Data Generation
Multiomic longitudinal data
Predictive Models
AI-powered interpretation
Clinical Insights
Actionable risk intelligence
Population Intelligence
Public-health scale impact
Clinical Value
Improved patient outcomes through earlier intervention.
Commercial Value
Recurring revenue across the patient journey.
Data Value
Longitudinal multiomic datasets compounding over time.
Strategic Value
Infrastructure positioning for therapeutic partnership.
Why Now
The convergence of oncology, AI, and precision medicine.
Molecular Biology
Maturation of cfDNA, methylation, and multiomic assays.
Artificial Intelligence
Models capable of integrating signals beyond human analysis.
Multiomics
Convergence of genomics, proteomics, and metabolomics at scale.
Precision Medicine
Therapies increasingly require biomarker-defined patients.
Healthcare Spending
Sustained growth in oncology investment globally.
Prevention Focus
Healthcare systems shifting toward early intervention.
Investment Thesis
Why Kiluma Biosciences.
01
Massive and Growing Market
Multi-hundred-billion-dollar global oncology and diagnostics opportunity expanding through 2030 and beyond.
02
Prevention-Focused Healthcare Shift
Payors, providers, and policy aligning around earlier detection and interception.
03
Multiomic Diagnostic Platform
Intercept IQ™ — a scalable architecture integrating cfDNA, epigenetics, proteomics, metabolomics, and AI.
04
Multiple Future Oncology Indications
Pancreatic beachhead with a roadmap extending across high-mortality cancers.
05
Companion Diagnostic Potential
Infrastructure positioned to enable biomarker-driven therapeutic development.
06
Strategic Acquisition Potential
Platform diagnostics have historically commanded premium strategic outcomes.
Ecosystem Value
Why early detection creates billions in value.
A successful cancer interception platform has the potential to create value across the entire healthcare ecosystem — impacting patients, providers, employers, insurers, pharmaceutical companies, and healthcare systems.
Platform
OncoIntercept™
Next-Generation Cancer Interception Platform
Value Flow
From biology to systemic efficiency.
Biological Change
Early Detection
Earlier Intervention
Improved Outcomes
Reduced Economic Burden
Greater Healthcare Efficiency
Compounding Advantage
The OncoIntercept Flywheel.
The long-term value of a diagnostic platform extends beyond testing revenue to include data generation, clinical intelligence, and ecosystem integration.
STEP 01
More Patients Tested
STEP 02
More Biomarker Data
STEP 03
More Clinical Insights
Center
OncoIntercept™
STEP 04
More Accurate Risk Models
STEP 05
Greater Physician Adoption
STEP 06
More Strategic Partnerships
Value Creation Pyramid
Beyond a single test.
Hover or tap a level to explore the layered platform opportunity.
LEVEL 6
Precision Oncology Infrastructure
Foundational layer powering biomarker-driven care across the healthcare ecosystem.
Reach
100%
Tier
1 / 6
Horizon
Long-term
The long-term vision is not a single test. It is building the infrastructure for the future of precision oncology.
Interactive · Impact Model
Model the impact of earlier detection.
Illustrative scenario. Move the slider to see how shifting cases from late to early stage drives systemic value.
Patients screened
250,000
Late-stage shift
80% → 50%
75,000
Patients shifted from late- to early-stage detection
$8.25B
Estimated lifetime cost-of-care reduction
26%
Reduction in average cost per patient population
Model assumes baseline late-stage rate of 80% at $150K avg. lifetime cost and early-stage cost of $40K, shifting to 50% late-stage with platform-enabled screening. Illustrative — not a clinical or financial guarantee.
Key Investor Message
Kiluma Biosciences is pursuing a future where cancer interception becomes a foundational component of healthcare — creating value for patients, providers, health systems, employers, insurers, pharmaceutical companies, and researchers worldwide.
Long-Term Vision
A future where cancer is identified earlier.
Kiluma Biosciences is pursuing a future where biological signals associated with cancer are identified earlier — enabling more informed clinical decisions, accelerating innovation, and improving outcomes for patients worldwide.
Contact Investor Relations